PROTEOM CLIN APPL 润色咨询

Proteomics Clinical Applications

出版年份：2007 年文章数：1204 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：2.0% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1096973, encodeId=129510969e380, content=文章投稿应该按照什么思路开始？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096974, encodeId=ea0610969e4c8, content=我的文章大概有几分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084608, encodeId=1d5f108460841, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：临床应用;蛋白质组<br>经验分享：投Proteomics推荐转投的，然后undereview半年，最后因为找不到审稿人 给拒了。哭。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75885622535, createdName=ms2000001704471729, createdTime=Mon Dec 27 10:10:39 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955100, encodeId=91da95510062, content=under review 1月后状态变为evaluating reviews，是不是太快了，估计没戏了。。。请过来人指点一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=P9icUbwX8uPhCUcWiazuqkJQ&s=100&t=1556431950, createdBy=87be5329630, createdName=a's's's's's, createdTime=Thu Apr 08 00:04:17 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548234, encodeId=835e5482344b, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：偏重蛋白质组学在临床方面的应用，是Proteomics的sister journal <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52bd1732430, createdName=寧靜致遠9a702681, createdTime=Sat Oct 14 16:24:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497518, encodeId=3d4749e518d5, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497064, encodeId=6ce049e064ef, content=这个期刊现在2.5分，比去年涨了不少，有没有希望能再上一步？冲到3分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gubing035, createdTime=Mon Jul 01 11:32:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=824613, encodeId=d5b882461389, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：审稿一月后状态变为evaluating reviews不知道有没有戏？博士毕业急需。请各位前辈指点。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e5414054, createdName=ms804033028710664, createdTime=Wed Mar 20 19:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=)]
    2021-12-27 MS54455111222

    文章投稿应该按照什么思路开始？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1096973, encodeId=129510969e380, content=文章投稿应该按照什么思路开始？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096974, encodeId=ea0610969e4c8, content=我的文章大概有几分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084608, encodeId=1d5f108460841, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：临床应用;蛋白质组<br>经验分享：投Proteomics推荐转投的，然后undereview半年，最后因为找不到审稿人 给拒了。哭。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75885622535, createdName=ms2000001704471729, createdTime=Mon Dec 27 10:10:39 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955100, encodeId=91da95510062, content=under review 1月后状态变为evaluating reviews，是不是太快了，估计没戏了。。。请过来人指点一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=P9icUbwX8uPhCUcWiazuqkJQ&s=100&t=1556431950, createdBy=87be5329630, createdName=a's's's's's, createdTime=Thu Apr 08 00:04:17 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548234, encodeId=835e5482344b, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：偏重蛋白质组学在临床方面的应用，是Proteomics的sister journal <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52bd1732430, createdName=寧靜致遠9a702681, createdTime=Sat Oct 14 16:24:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497518, encodeId=3d4749e518d5, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497064, encodeId=6ce049e064ef, content=这个期刊现在2.5分，比去年涨了不少，有没有希望能再上一步？冲到3分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gubing035, createdTime=Mon Jul 01 11:32:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=824613, encodeId=d5b882461389, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：审稿一月后状态变为evaluating reviews不知道有没有戏？博士毕业急需。请各位前辈指点。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e5414054, createdName=ms804033028710664, createdTime=Wed Mar 20 19:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=)]
    2021-12-27 rayms

    我的文章大概有几分？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1096973, encodeId=129510969e380, content=文章投稿应该按照什么思路开始？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096974, encodeId=ea0610969e4c8, content=我的文章大概有几分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084608, encodeId=1d5f108460841, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：临床应用;蛋白质组<br>经验分享：投Proteomics推荐转投的，然后undereview半年，最后因为找不到审稿人 给拒了。哭。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75885622535, createdName=ms2000001704471729, createdTime=Mon Dec 27 10:10:39 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955100, encodeId=91da95510062, content=under review 1月后状态变为evaluating reviews，是不是太快了，估计没戏了。。。请过来人指点一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=P9icUbwX8uPhCUcWiazuqkJQ&s=100&t=1556431950, createdBy=87be5329630, createdName=a's's's's's, createdTime=Thu Apr 08 00:04:17 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548234, encodeId=835e5482344b, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：偏重蛋白质组学在临床方面的应用，是Proteomics的sister journal <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52bd1732430, createdName=寧靜致遠9a702681, createdTime=Sat Oct 14 16:24:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497518, encodeId=3d4749e518d5, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497064, encodeId=6ce049e064ef, content=这个期刊现在2.5分，比去年涨了不少，有没有希望能再上一步？冲到3分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gubing035, createdTime=Mon Jul 01 11:32:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=824613, encodeId=d5b882461389, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：审稿一月后状态变为evaluating reviews不知道有没有戏？博士毕业急需。请各位前辈指点。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e5414054, createdName=ms804033028710664, createdTime=Wed Mar 20 19:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=)]
    2021-12-27 ms2000001704471729

    审稿速度:6.0 | 投稿命中率:25.0
    偏重的研究方向：临床应用;蛋白质组
    经验分享：投Proteomics推荐转投的，然后undereview半年，最后因为找不到审稿人 给拒了。哭。。。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1096973, encodeId=129510969e380, content=文章投稿应该按照什么思路开始？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096974, encodeId=ea0610969e4c8, content=我的文章大概有几分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084608, encodeId=1d5f108460841, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：临床应用;蛋白质组<br>经验分享：投Proteomics推荐转投的，然后undereview半年，最后因为找不到审稿人 给拒了。哭。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75885622535, createdName=ms2000001704471729, createdTime=Mon Dec 27 10:10:39 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955100, encodeId=91da95510062, content=under review 1月后状态变为evaluating reviews，是不是太快了，估计没戏了。。。请过来人指点一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=P9icUbwX8uPhCUcWiazuqkJQ&s=100&t=1556431950, createdBy=87be5329630, createdName=a's's's's's, createdTime=Thu Apr 08 00:04:17 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548234, encodeId=835e5482344b, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：偏重蛋白质组学在临床方面的应用，是Proteomics的sister journal <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52bd1732430, createdName=寧靜致遠9a702681, createdTime=Sat Oct 14 16:24:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497518, encodeId=3d4749e518d5, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497064, encodeId=6ce049e064ef, content=这个期刊现在2.5分，比去年涨了不少，有没有希望能再上一步？冲到3分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gubing035, createdTime=Mon Jul 01 11:32:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=824613, encodeId=d5b882461389, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：审稿一月后状态变为evaluating reviews不知道有没有戏？博士毕业急需。请各位前辈指点。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e5414054, createdName=ms804033028710664, createdTime=Wed Mar 20 19:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=)]
    2021-04-08 a's's's's's

    under review 1月后状态变为evaluating reviews，是不是太快了，估计没戏了。。。请过来人指点一下

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1096973, encodeId=129510969e380, content=文章投稿应该按照什么思路开始？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096974, encodeId=ea0610969e4c8, content=我的文章大概有几分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084608, encodeId=1d5f108460841, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：临床应用;蛋白质组<br>经验分享：投Proteomics推荐转投的，然后undereview半年，最后因为找不到审稿人 给拒了。哭。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75885622535, createdName=ms2000001704471729, createdTime=Mon Dec 27 10:10:39 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955100, encodeId=91da95510062, content=under review 1月后状态变为evaluating reviews，是不是太快了，估计没戏了。。。请过来人指点一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=P9icUbwX8uPhCUcWiazuqkJQ&s=100&t=1556431950, createdBy=87be5329630, createdName=a's's's's's, createdTime=Thu Apr 08 00:04:17 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548234, encodeId=835e5482344b, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：偏重蛋白质组学在临床方面的应用，是Proteomics的sister journal <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52bd1732430, createdName=寧靜致遠9a702681, createdTime=Sat Oct 14 16:24:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497518, encodeId=3d4749e518d5, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497064, encodeId=6ce049e064ef, content=这个期刊现在2.5分，比去年涨了不少，有没有希望能再上一步？冲到3分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gubing035, createdTime=Mon Jul 01 11:32:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=824613, encodeId=d5b882461389, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：审稿一月后状态变为evaluating reviews不知道有没有戏？博士毕业急需。请各位前辈指点。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e5414054, createdName=ms804033028710664, createdTime=Wed Mar 20 19:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=)]
    2017-10-14 寧靜致遠9a702681

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享：偏重蛋白质组学在临床方面的应用，是Proteomics的sister journal

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1096973, encodeId=129510969e380, content=文章投稿应该按照什么思路开始？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096974, encodeId=ea0610969e4c8, content=我的文章大概有几分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084608, encodeId=1d5f108460841, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：临床应用;蛋白质组<br>经验分享：投Proteomics推荐转投的，然后undereview半年，最后因为找不到审稿人 给拒了。哭。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75885622535, createdName=ms2000001704471729, createdTime=Mon Dec 27 10:10:39 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955100, encodeId=91da95510062, content=under review 1月后状态变为evaluating reviews，是不是太快了，估计没戏了。。。请过来人指点一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=P9icUbwX8uPhCUcWiazuqkJQ&s=100&t=1556431950, createdBy=87be5329630, createdName=a's's's's's, createdTime=Thu Apr 08 00:04:17 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548234, encodeId=835e5482344b, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：偏重蛋白质组学在临床方面的应用，是Proteomics的sister journal <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52bd1732430, createdName=寧靜致遠9a702681, createdTime=Sat Oct 14 16:24:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497518, encodeId=3d4749e518d5, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497064, encodeId=6ce049e064ef, content=这个期刊现在2.5分，比去年涨了不少，有没有希望能再上一步？冲到3分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gubing035, createdTime=Mon Jul 01 11:32:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=824613, encodeId=d5b882461389, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：审稿一月后状态变为evaluating reviews不知道有没有戏？博士毕业急需。请各位前辈指点。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e5414054, createdName=ms804033028710664, createdTime=Wed Mar 20 19:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=)]
    2013-07-01 pingjian888

    跨过2分了，明年会不会再略冲冲，很有希望

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1096973, encodeId=129510969e380, content=文章投稿应该按照什么思路开始？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096974, encodeId=ea0610969e4c8, content=我的文章大概有几分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084608, encodeId=1d5f108460841, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：临床应用;蛋白质组<br>经验分享：投Proteomics推荐转投的，然后undereview半年，最后因为找不到审稿人 给拒了。哭。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75885622535, createdName=ms2000001704471729, createdTime=Mon Dec 27 10:10:39 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955100, encodeId=91da95510062, content=under review 1月后状态变为evaluating reviews，是不是太快了，估计没戏了。。。请过来人指点一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=P9icUbwX8uPhCUcWiazuqkJQ&s=100&t=1556431950, createdBy=87be5329630, createdName=a's's's's's, createdTime=Thu Apr 08 00:04:17 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548234, encodeId=835e5482344b, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：偏重蛋白质组学在临床方面的应用，是Proteomics的sister journal <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52bd1732430, createdName=寧靜致遠9a702681, createdTime=Sat Oct 14 16:24:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497518, encodeId=3d4749e518d5, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497064, encodeId=6ce049e064ef, content=这个期刊现在2.5分，比去年涨了不少，有没有希望能再上一步？冲到3分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gubing035, createdTime=Mon Jul 01 11:32:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=824613, encodeId=d5b882461389, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：审稿一月后状态变为evaluating reviews不知道有没有戏？博士毕业急需。请各位前辈指点。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e5414054, createdName=ms804033028710664, createdTime=Wed Mar 20 19:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=)]
    2013-07-01 gubing035

    这个期刊现在2.5分，比去年涨了不少，有没有希望能再上一步？冲到3分？

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1096973, encodeId=129510969e380, content=文章投稿应该按照什么思路开始？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096974, encodeId=ea0610969e4c8, content=我的文章大概有几分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084608, encodeId=1d5f108460841, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：临床应用;蛋白质组<br>经验分享：投Proteomics推荐转投的，然后undereview半年，最后因为找不到审稿人 给拒了。哭。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75885622535, createdName=ms2000001704471729, createdTime=Mon Dec 27 10:10:39 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955100, encodeId=91da95510062, content=under review 1月后状态变为evaluating reviews，是不是太快了，估计没戏了。。。请过来人指点一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=P9icUbwX8uPhCUcWiazuqkJQ&s=100&t=1556431950, createdBy=87be5329630, createdName=a's's's's's, createdTime=Thu Apr 08 00:04:17 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548234, encodeId=835e5482344b, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：偏重蛋白质组学在临床方面的应用，是Proteomics的sister journal <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52bd1732430, createdName=寧靜致遠9a702681, createdTime=Sat Oct 14 16:24:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497518, encodeId=3d4749e518d5, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497064, encodeId=6ce049e064ef, content=这个期刊现在2.5分，比去年涨了不少，有没有希望能再上一步？冲到3分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gubing035, createdTime=Mon Jul 01 11:32:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=824613, encodeId=d5b882461389, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：审稿一月后状态变为evaluating reviews不知道有没有戏？博士毕业急需。请各位前辈指点。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e5414054, createdName=ms804033028710664, createdTime=Wed Mar 20 19:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=)]
    2013-03-20 ms804033028710664

    审稿速度:6.0 | 投稿命中率:50.0
    经验分享：审稿一月后状态变为evaluating reviews不知道有没有戏？博士毕业急需。请各位前辈指点。

    0

共11条页码: 1/2页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分